目的 探究坎地沙坦治療老年原發(fā)性高血壓及其并發(fā)癥的臨床療效。方法 選取2011年1月—2014年1月冀中能源峰峰集團有限公司總醫(yī)院收治的原發(fā)性高血壓患者150例, 隨機分為對照組和治療組, 每組75例。對照組患者給予常規(guī)治療, 治療組患者在此基礎上口服坎地沙坦酯片, 1片/次, 1次/d。兩組患者均連續(xù)治療24周。比較兩組的臨床療效, 同時檢測兩組患者左心室舒張末期內徑(LVDd)、左心室舒張末期后壁厚度(LVPWT)、左心室舒張末期室間隔厚度(VST)、最大管腔內膜界面與中層外膜界面之間的距離(IMT值)的變化。結果 對照組和治療組總有效率分別為81.33%、96.00%, 兩組比較差異有統(tǒng)計學意義(P<0.05)。治療后, 兩組收縮壓和舒張壓均明顯下降, 同組治療前后差異有統(tǒng)計學意義(P<0.05), 且治療組的下降程度大于對照組, 兩組比較差異有統(tǒng)計學意義(P<0.05)。治療后, 治療組LVDd、LVPWT、VST、IMT值均較治療前降低, 差異有統(tǒng)計學意義(P<0.05), 但對照組治療前后這些指標變化無統(tǒng)計學意義;治療后, 治療組LVDd、LVPWT、VST、IMT值低于對照組, 兩組比較差異有統(tǒng)計學意義(P<0.05)。結論 坎地沙坦治療老年原發(fā)性高血壓及其并發(fā)癥具有較好臨床療效, 可顯著降低患者血壓, 同時還可改善動脈粥樣硬化和左心室肥大情況, 值得臨床推廣應用。

Objective To investigate the clinical effect of candesartan in treatment of elderly primary hypertension and its complications. Methods The patients with primary hypertension (150 cases) of General Hospital of Hebei Central Energy Fengfeng Group Co., LTD from January 2011 to January 2014 were randomly divided into control and treatment groups, and each group had 75 cases. The patients in the control group were given conventional therapy. The patients in the treatment group were po administered with Candesartan Cilexetil Tablets at the basis of control group, 1 tablet/time, once daily. The patients in two groups were treated for 24 weeks. After treatment, the efficacy was evaluated, while the changes of LVDd, LVPWT, VST, and IMT were detected. Results The efficacies in the control and treatment groups were 81.33% and 96.00%, respectively, and there were differences between the two groups (P < 0.05). After treatment, systolic blood pressure and diastolic blood pressure in two groups significantly decreased, and the difference was statistically significant in the same group before and after treatment (P < 0.05). Systolic blood pressure and diastolic blood pressure in treatment group decreased more than those in the control group, and there were differences between two groups (P < 0.05). After treatment, LVDd, LVPWT, VST, and IMT in treatment group significantly decreased, and the difference was statistically significant in the same group before and after treatment (P < 0.05). But there was no difference before and after treatment about these indexes in the control group. After treatment, the values of LVDd, LVPWT, VST, and IMT in the treatment group were lower than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Candesartan has the good clinical effect in treatment of elderly primary hypertension and its complications, and can significantly decrease the blood pressure and improve the condition of atherosclerosis and left ventricular hypertrophy, which is worth clinical promotion.